The sound of rain may feel romantic to some, but for parents? It’s a seasonal alarm bell. Not just puddles and power cuts, an annual wave of infections that hit kids the hardest.

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...